Rapid and noninvasive metabonomic characterization of inflammatory bowel disease.

By Julian R. Marchesi, Edward C. Holmes, F. Khan, S. Kochhar, P. Scanlan, F. Shanahan, Ian A. Wilson, Yulan Wang. Journal of Proteome Research, 2007

638 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/96c63938608823b18f493cf9f4a7ec0158620542

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut (2016, background): “…rectale, F. prausnitzii, and/or R. intestinalis is markedly decreased in IBD patients (Morgan et al., 2012; Eeckhaut et al., 2013; Gevers et al., 2014) and that such patients have lower concentrations of butyrate in their feces than healthy individuals (Marchesi et al., 2007; Nemoto et al., 2012).”
Gut microbiome-host interactions in health and disease (2011, background): “Also, the gut microbiome has been directly implicated in the etiopathogenesis of a number of pathological states as diverse as obesity [7], circulatory disease [8], inflammatory bowel diseases (IBDs) [9] and autism [10] (Figure 1).”
Host genetic variation impacts microbiome composition across human body sites (2015, background): “There is great variability in the microbiome across individuals, with some differences associated with chronic conditions, including obesity, diabetes, and inflammatory bowel disease (IBD) [7–12].”
The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation (2016, background): “Dysbiosis of the microbiome has been associated with a large number of health problems and causally implicated in metabolic, immunological, and developmental disorders, as well as susceptibility to development of infectious diseases [4–11].”
Shifting the balance: antibiotic effects on host–microbiota mutualism (2011, background): “Intriguingly, reduced concentrations of prostaglandin E 2 metabolites have been observed in patients with Crohn's disease, along with a disrupted microbiota, reduced butyrate production and uncontrolled intestinal inflammatio”